SLXN — Silexion Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Silexion Therapeutics Announces 1-For-10 Reverse Share Split
Brief: Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer
Brief: Silexion Therapeutics Receives Positive Feedback From German Health Authority On Design Of Phase 2/3 Clinical
Brief: Silexion To Begin Phase 2/3 Pancreatic Cancer Clinical Trial In Q2 2026
Silexion Therapeutics climbs on promising cancer drug data
Brief: Silexion Therapeutics Corp Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: Silexion Therapeutics Says Nasdaq Confirms Co's Compliance For Continued Listing
Silexion Therapeutics jumps after preclinical trial data for pancreatic cancer treatment
Brief: Silexion Therapeutics Announces Pricing Of $6.0 Million Public Offering
Silexion Therapeutics jumps after preclinical trial data for pancreatic cancer treatment
Brief: Silexion Reports Positive Preclinical Data Demonstrating SIL204's Reach
Brief: Silexion Therapeutics Corp - Phase 2/3 Trials To Start In First Half Of 2026
Brief: Silexion Therapeutics Posts New Preclinical Data Showing Up To 97% Inhibition Of Cancer Cell Growth
Brief: Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update
Brief: Silexion Therapeutics Announces Collaboration With Global Therapeutics Leader Catalent On Advanced Sirna Formulation Development & Clinical Manufacturing Activities
Brief: Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204